Acadia Pharmaceuticals’ (ACAD) share price has flagged since an April story by CNN that highlighted serious and sometimes fatal side effects tied to Nuplazid, its recently approved treatment for symptoms of Parkinson’s disease. Now FDA Commissioner Scott Gottlieb has promised to “go back and take another look.”
And that could mean bringing Nuplazid in front of another FDA advisory panel, which would allow outside experts to take a second, closer look at the drug’s safety profile.
Gottlieb mentioned the FDA’s reconsideration of the issue before a House committee last week, but it seemed to escape most everyone’s attention until yesterday, when Acadia’s stock price fell another 22 percent. An FDA spokeswoman confirmed via email that the agency “is conducting an evaluation of available information about Nuplazid. This review has been going on for several weeks. We have nothing more to share at this time.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
